Skip to main content
Fig. 4 | Cancer Cell International

Fig. 4

From: Breast cancer scoring based on a multiplexed profiling of soluble and cell-associated (immune) markers facilitates the prediction of pembrolizumab therapy

Fig. 4

Checkpoint expression on T cells in the peripheral blood and tumor tissue. (A) Immune checkpoint marker (LAG-3, PD-1, TIM-3) expression was analyzed by flow cytometry in the peripheral blood of healthy donors and blood and tumor of TNBC patients. (B) Immune checkpoint marker (LAG-3, PD-1, TIM-3) expression (B) and co-expression (C) of BC patients (TNBC, Luminal B, HER2+) on CD4+ and CD8+ T cells are displayed. Data are shown as mean +/-SD and p-values were calculated by Kruskal-Wallis-test (Dunn´s multiple comparisons test); * p ≤ 0.05; **** p ≤ 0.0001; red symbols represent Luminal B BC patients with HER2 expression. HD = peripheral blood of healthy donors; PB = patient derived peripheral blood; PT = patient derived tumor

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us